Innovative Methodology Translates Noncoding DNA in Colorectal Cancer
By LabMedica International staff writers Posted on 05 Aug 2014 |
Although the genetic origins of cancers have been studied for a long time, scientists were not able to measure the role of noncoding regions of the genome until now.
Cancer is a disease of the genome resulting from a combination of genetic modifications or mutations which are inherited from parents with strong or weak predispositions to develop certain kinds of cancer and in addition accumulate new mutations in cells throughout an individual’s lifespan.
Geneticists at the University of Geneva (Switzerland) used genome sequencing technology to compare the ribonucleic acid (RNA) between healthy tissue and tumor tissue from 103 patients. They searched for regulatory elements present in the vast, noncoding portion of the genome that impact the development of colorectal cancer. The goal was to identify the effect, present only in cancerous tissue, of acquired mutations whose activation would have triggered the disease and it is the first study of this scale to examine the noncoding genome of cancer patients. RNA quality was assessed using the Bioanalyzer RNA 6000 Nano Kit (Agilent Technologies; Santa Clara, CA, USA) and RNA quantity was measured with the Qubit 2.0 fluorometer using the RNA Broad range kit (Invitrogen; Carlsbad, CA, USA) and messenger RNA (mRNA) sequencing was done on a HiSeq 2000 platform (Illumina; San Diego, CA, USA).
The team was able to identify two kinds of noncoding mutations that have an impact on the development of colorectal cancer. They found, on one hand, hereditary regulatory variants that are not active in healthy tissue, but are activated in tumors and seem to contribute to cancer progression. It shows that the inherited genome not only affects the predisposition towards developing cancer, but also has an influence on its progression. On the other hand, the scientists identified effects of acquired mutations on the regulation of gene expression that affect the genesis and progression of colorectal tumors.
Halit Ongen, PhD, the lead author of this study, said, “The elements responsible for the development and progression of cancers located in the noncoding genome are as important as those found in the coding regions of the genome. Therefore, analyzing genetic factors in our whole genome, and not only in the coding regions as it was done before, gives us a much more comprehensive knowledge of the genetics behind colorectal cancer.” The study was published on July 23, 2014, in the journal Nature.
Related Links:
University of Geneva
Agilent Technologies
Invitrogen
Cancer is a disease of the genome resulting from a combination of genetic modifications or mutations which are inherited from parents with strong or weak predispositions to develop certain kinds of cancer and in addition accumulate new mutations in cells throughout an individual’s lifespan.
Geneticists at the University of Geneva (Switzerland) used genome sequencing technology to compare the ribonucleic acid (RNA) between healthy tissue and tumor tissue from 103 patients. They searched for regulatory elements present in the vast, noncoding portion of the genome that impact the development of colorectal cancer. The goal was to identify the effect, present only in cancerous tissue, of acquired mutations whose activation would have triggered the disease and it is the first study of this scale to examine the noncoding genome of cancer patients. RNA quality was assessed using the Bioanalyzer RNA 6000 Nano Kit (Agilent Technologies; Santa Clara, CA, USA) and RNA quantity was measured with the Qubit 2.0 fluorometer using the RNA Broad range kit (Invitrogen; Carlsbad, CA, USA) and messenger RNA (mRNA) sequencing was done on a HiSeq 2000 platform (Illumina; San Diego, CA, USA).
The team was able to identify two kinds of noncoding mutations that have an impact on the development of colorectal cancer. They found, on one hand, hereditary regulatory variants that are not active in healthy tissue, but are activated in tumors and seem to contribute to cancer progression. It shows that the inherited genome not only affects the predisposition towards developing cancer, but also has an influence on its progression. On the other hand, the scientists identified effects of acquired mutations on the regulation of gene expression that affect the genesis and progression of colorectal tumors.
Halit Ongen, PhD, the lead author of this study, said, “The elements responsible for the development and progression of cancers located in the noncoding genome are as important as those found in the coding regions of the genome. Therefore, analyzing genetic factors in our whole genome, and not only in the coding regions as it was done before, gives us a much more comprehensive knowledge of the genetics behind colorectal cancer.” The study was published on July 23, 2014, in the journal Nature.
Related Links:
University of Geneva
Agilent Technologies
Invitrogen
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer